Xidian Pharmaceutical Obtains Marketing Authorization Holder Change for Potassium Chloride Granules

Corporate Action
โดย Jiemian·CN·Read original
Summary · why it matters

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. announced on September 3, 2026, that the marketing authorization holder for its potassium chloride granules has been approved by the National Medical Products Administration to change from Suzhou Longcare Biotechnology Co., Ltd. to Xidian Pharmaceutical itself. The product specification is 1.5 grams of potassium chloride per sachet, used for the treatment and prevention of hypokalemia. Its approval number, manufacturing site, formulation, production process, and quality standards remain unchanged. The company stated that approval of this product will further enrich its product line and enhance market competitiveness, but product sales are still affected by industry policies, tendering and procurement, and changes in the market environment, and uncertainties remain.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

苏州朗科生物技术股份有限公司Private± Mixed
Regulationrelevance

Suzhou Longcare Biotechnology is the outgoing marketing authorization holder being replaced by Xidian Pharmaceutical.

© 2026 MarketDXNews